Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

VivoSim to Carry Forward Organovo 3D Bioprinting
Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements
Organovo Provides Business Update
Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company
Organovo Announces Reverse Stock Split
Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors
Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises
Organovo's FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.